Advertisement

Reactions Weekly

, Volume 1737, Issue 1, pp 205–205 | Cite as

Multiple drugs

Cutaneous scleroderma, rheumatoid arthritis and myositis: 3 case reports
Case report
  • 76 Downloads
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

In a case series involving male to female transitioned (transsexual) patients, a 35-year-old man developed cutaneous scleroderma following treatment with norethisterone/mestranol [Norinyl-1R]; a 49-year-old man developed cutaneous scleroderma/ rheumatoid arthritis overlap syndrome following treatment with conjugated estrogen [Premarin] and ethinylestradiol/gestodene [Femodene] and a 43-year-old man developed cutaneous scleroderma/myositis overlap syndrome (one patient) following treatment with conjugated estradiol valerate and triptorelin [Decapeptyl; dosages and routes not stated].

Case 1: The 35-year-old man had undergone male to female transsexual transition five years prior. At the beginning of the transition, he had started hormonal therapy with norethisterone/mestranol....

Reference

  1. Campochiaro C, et al. Development of systemic sclerosis in transgender females: A case series and review of the literature. Clinical and Experimental Rheumatology 36 (Suppl. 113): S50-S52, No. 113, Jan 2018. Available from: URL: http://www.clinexprheumatol.org/article.asp?a=12276 - United Kingdom

Copyright information

© Springer Nature Switzerland AG 2019

Personalised recommendations